/

Società

Ad

Non verificato

AdvanCell

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

9 comunicati stampa

Guarda tutti i comunicati

02/02/2026

Mercato del lavoro

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need

Fonte

Emittente

1.00

0

08/12/2025

Industria

Terza età

Medicina - Varie

Biotecnologia

Medicina nucleare

Salute

Vetrine/Shopping

Farmaceutica

Oncologia

AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies

Fonte

Emittente

1.00

0

02/12/2025

Eventi

Industria

Oncologia

Salute

Igiene alimentare

Medicina nucleare

Medicina - Varie

Farmaceutica

Biotecnologia

AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer

Fonte

Emittente

1.00

0

11/11/2025

Scienza

Medicina nucleare

Farmaceutica

Oncologia

Vetrine/Shopping

Comunicazione

Medicina - Varie

Biotecnologia

Salute

Eventi

Industria

AdvanCell to participate in Jefferies Global Healthcare Conference in London

Fonte

Emittente

1.00

0

21/10/2025

Eventi

Industria

Oncologia

Salute

Sanità

Medicina nucleare

Medicina - Varie

Farmaceutica

Biotecnologia

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

Fonte

Emittente

1.00

0

12/10/2025

Oncologia

Salute

Sanità

Medicina nucleare

Medicina - Varie

Farmaceutica

Biotecnologia

Eventi

Fiere

Industria

AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 2025

Fonte

Emittente

1.00

0

14/04/2025

Scienza

Medicina nucleare

Biotecnologia

Farmaceutica

Oncologia

Salute

Medicina - Varie

AdvanCell Proudly Announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’

Fonte

Emittente

1.00

0

10/02/2025

Medicina nucleare

Scienza

Farmaceutica

Oncologia

HIV, AIDS e malattie autoimmuni

Sanità

Biotecnologia

Biologia

Management

Medicina sportiva

Medicina - Varie

Salute

Mercato del lavoro

Industria

AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer

Fonte

Emittente

1.00

0

03/02/2025

Oncologia

Salute

Biologia

Medicina - Varie

Sanità

Farmaceutica

Biotecnologia

Industria

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0